1. Iida M, Tsuboi K, Niwa T, et al: Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Breast Cancer 2019; 26: 272–281
2. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2000; 7: 57-70
3. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2011; 4: 646-74
4. Rennstam K, Ringberg A, et al: Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer 2010; 49: 78-90
5. Carvalho R, Paredes J, et al: Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling. Semin Cancer Biol. 2020; 60: 294-301.
6. Marsigliante S, Vetrugno C, et al: CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol. 2013; 228(9): 1873-83.
7. Warburg O. THE METABOLISM OF CARCINOMA CELLS. Cancer Research 1925
8. Takashima Y, Hayano A, Yamanaka R: Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells. Clin Cancer Res. 2020; 26(11): 2754-2766
9. Ralf J, Navdeep S: Fundamentals of cancer metabolism. DeBerardinis and Chandel Sci. Adv. 2016; 2: e1600200
10. Harada-Shoji N, Soga T, Tada H, et al: A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: A pilot study. Metabolomics 2019; 15: 147
11. Eagle H: Nutrition needs of mammalian cells in tissue culture. Science 1955; 122: 501–504
12. Sato M, Harada-Shoji N, Toyohara T, et al: L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Sci. Rep. 2021; 11: 589
13. Wang Q, Holst J: L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia. Am. J. Cancer Res. 2015; 5: 1281–1294
14. Liang Z, Cho HT, Williams L, et al: Potential biomarker of L-type amino acid transporter 1 in breast cancer progression. Nucl. Med. Mol. Imaging 2011; 45: 93–102
15. Kanai Y, Segawa H, Miyamoto K, et al: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 1998; 273: 23629–23632
16. Hafliger P, Charles RP: The L-type amino acid transporter LAT1-an emerging target in cancer. Int. J. Mol. Sci. 2019; 20: 2428
17. Saito Y, Li L, Coyaud E, et al: LLGL2 rescues nutrient stress by promoting leucine uptake in ER(+) breast cancer. Nature 2019; 569: 275–279
18. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012; 366: 520–529
19. Wang Q, Bailey CG, Ng C, et al: Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 2011; 71: 7525–7536
20. Zhang BK, Moran AM, Bailey CG, et al: EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer. Cell Commun. Signal. 2019; 17: 83
21. Dae-Woong Y, Seul A, Min-Gyeong P, et al: JPH203, an L-Type Amino Acid Transporter 1-Selective Compound, Induces Apoptosis of YD-38 Human Oral Cancer Cells. J Pharmacol Sci. 2014; 124: 208-217
22. Okano N, Naruge D, Kawai K, et al: First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest. New Drugs 2020; 38: 1495–1506
23. Horii R, Akiyama F: Histological assessment of therapeutic response in breast cancer. Breast Cancer 2016; 23: 540–545
24. Nosaka K, Makishima K, Sakabe T, et al: Upregulation of glucose and amino acid transporters in micropapillary carcinoma. Histol. Histopathol. 2019; 34: 1009–1014
25. Fujiki N, Konno H, Kaneko Y, et al: Estrogen Response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estro-gen-deprivation resistant mechanisms. J. Steroid Biochem. Mol. Biol. 2014; 139: 61–72
26. Tsuboi, K, Kaneko Y, Nagatomo T, et al: Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer. J. Steroid Biochem. Mol. Biol. 2017; 167: 115–125
27. Iwabuchi E, Miki Y, Ono K, et al: In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). J. Steroid Biochem. Mol. Biol. 2017; 165: 159–169
28. Shibahara Y, Miki Y, Onodera Y, et al: Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a micro RNA targeting CYP19A1. J. Pathol. 2012; 227: 357–366
29. Hirayama A, Kami K, Sugimoto M, et al: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009; 69: 4918–4925
30. Habermeier A, Graf J, Sandhöfer BF, et al: System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids 2015; 47: 335–344
31. Salisbury TB, Arthur S: The regulation and function of the L-type amino acid transporter 1 (LAT1) in cancer. Int. J. Mol. Sci. 2018; 19: 2373
32. Furuya M, Horiguchi J, Nakajima H, et al: Correlation of L-type amino acid transporter 1 and CD98 ex-pression with triple negative breast cancer prognosis. Cancer Sci. 2012; 103: 382–819
33. Sevigny CM, Sengupta S, Luo Z, et al: SLCs contribute to endocrine resistance in breast cancer: Role of SLC7A5 (LAT1). bioRxiv 2019; 10: 1101/555342
34. Ananieva EA, Wilkinson AC: Branched-chain amino acid metabolism in cancer. Curr. Opin. Clin. Nutr. Metab. Care 2018; 21: 64–70
35. Ananieva E: Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J. Biol. Chem. 2015; 6: 281–289
36. Higuchi K, Sakamoto S, Ando K, et al: Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci. Rep. 2019; 9: 16776
37. Xu M, Sakamoto S, Matsushima J, et al: Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells. J. Urol. 2016; 195: 1588–1597
38. Kongpracha P, Nagamori S, Wiriyasermkul P, et al: Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter1 (LAT1). J. Pharmacol. Sci. 2017; 133: 96–103
39. Häfliger P, Graff J, Rubin M, et al: The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. J. Exp. Clin. Cancer Res. 2018; 37: 234
40. Yun DW, Lee SA, Park MG, et al: JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. J. Pharmacol. Sci. 2014; 124: 208–217
41. Kaira K, Oriuchi N, Takahashi T, et al: LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am. J. Transl. Res. 2011; 3: 468–478